Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences, Inc. (CRBU) is a clinical-stage biotechnology company pioneering advancements in genome engineering. Leveraging revolutionary CRISPR-Cas9 technology, Caribou specializes in developing innovative cellular engineering solutions. Their technology, which pairs Cas9 with guide RNA to facilitate precise DNA modifications, is being harnessed for sophisticated gene knock-outs and knock-ins. Caribou's tools provide transformative capabilities across various sectors, including biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.
At the forefront of biopharmaceutical innovation, Caribou is dedicated to applying its proprietary CRISPR hybrid RNA-DNA (chRDNA) platform to create next-generation genome-edited cell therapies. Their pipeline includes allogeneic CAR-T and CAR-NK cell therapies, aimed at treating patients with hematologic malignancies and solid tumors.
Recent milestones include the FDA's feedback on a Phase 3 trial for CB-010, an allogeneic anti-CD19 CAR-T cell therapy targeting large B cell lymphoma (LBCL). The ongoing ANTLER Phase 1 trial has shown promising results, with CB-010 receiving Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations. Caribou is also expanding CB-010's potential application to lupus nephritis and extrarenal lupus, with a GALLOP Phase 1 trial planned for late 2024.
Financially, Caribou reported a net loss of $41.2 million for Q1 2024, with $345.9 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q1 2026. Their strategic partnerships, including a collaboration with Pfizer, have bolstered their financial standing.
Caribou continues to push the boundaries of genome editing with its chRDNA technology, significantly improving the precision of genome edits. Their commitment to transforming patient lives through cutting-edge science positions them as a leader in the biotech landscape.
Caribou Biosciences, Inc. (Nasdaq: CRBU) announced the start of the dose expansion phase of its CB-010 ANTLER trial for second-line large B cell lymphoma (LBCL) patients. CB-010 is the first allogeneic CAR-T therapy assessed in this setting. The dose escalation was well tolerated, with no dose-limiting toxicities observed at the highest dose level. Earlier cohorts showed promising results, with complete responses in 6 out of 6 patients treated. The trial will evaluate two dose levels on about 30 patients to establish the recommended Phase 2 dose and aims to address the challenges associated with autologous therapies. An update is expected in H2 2023.
Caribou Biosciences (CRBU) reported Q4 and full-year 2022 results, highlighting ongoing progress in its clinical pipeline. As of December 31, 2022, the company held $317 million in cash and equivalents, sufficient to fund operations into 2025. The lead therapy, CB-010, showed promising results in treating relapsed/refractory B-cell non-Hodgkin lymphoma, with notable complete response rates. Recent advancements include the activation of clinical sites for CB-011 and the initiation of IND-enabling studies for CB-012, targeting acute myeloid leukemia. However, a net loss of $99.4 million for 2022 raises concerns.
Caribou Biosciences (Nasdaq: CRBU), a leader in CRISPR genome-editing, announced that its CEO, Rachel Haurwitz, will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 10:40 am EDT. This event will showcase Caribou's advancements in gene-editing technologies, particularly their innovative CRISPR hybrid RNA-DNA guides (chRDNAs), aimed at enhancing precision in genome editing. The live webcast can be accessed on Caribou's website, available for 30 days post-event. The company focuses on developing transformative therapies for serious diseases using its proprietary technology.
Caribou Biosciences (Nasdaq: CRBU) announced that CEO Rachel Haurwitz, Ph.D., will participate in three upcoming investor conferences in February 2023. The conferences include the Guggenheim Oncology Conference on February 9 at 10:45 AM EST, the SVB Securities Global Biopharma Conference on February 14 at 5:00 PM EST, and Citi's 2023 Oncology Leadership Summit on February 22 at 2:00 PM EST. All events offer webcasts for attendees. Caribou is known for its next-generation CRISPR genome-editing platform, particularly its innovative chRDNA technology, enhancing precision in therapies for hematologic malignancies and solid tumors.
Caribou Biosciences, Inc. (Nasdaq: CRBU) will present a corporate update by CEO Rachel Haurwitz at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 11:15 am PST. A live webcast will be available on Caribou's website, with an archived version accessible for 30 days post-event. Caribou is focused on advancing CRISPR genome-editing technologies, specifically its chRDNA platform, to develop innovative therapies for cancer treatment.
Caribou Biosciences announced promising long-term results from the ongoing ANTLER Phase 1 trial for its allogeneic CAR-T therapy, CB-010, targeting relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). Twelve-month data show that 100% of patients in cohort 1 achieved a complete response, with two maintaining durable responses for up to 18 months. The FDA granted CB-010 RMAT and Fast Track designations, enhancing its development pathway. Currently, the trial is enrolling patients at a higher dose level, indicating positive progress in patient recruitment and potential therapeutic efficacy.
Caribou Biosciences, Inc. (Nasdaq: CRBU) has announced the target selection for its allogeneic anti-ROR1 CAR-NK cell therapy, CB-020, to be presented at the AACR-JCA Conference. The preclinical data suggests ROR1 could be a viable target for solid tumors, enhancing antitumor activity via innovative armoring strategies. These strategies aim to improve NK cell survival and efficacy against tough tumor environments. The research indicates significant tumor burden reduction with CB-020 compared to unmodified NK cells. This advancement highlights Caribou's utilization of its proprietary chRDNA CRISPR technology.
Caribou Biosciences (Nasdaq: CRBU) announced FDA has granted its CB-010 therapy both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). This therapy, the first allogeneic CAR-T with a PD-1 knockout, is undergoing the ANTLER Phase 1 trial. Three out of six patients had a durable complete response at six months. These designations aim to expedite development and regulatory review for promising treatments addressing significant patient needs.
Caribou Biosciences (CRBU) reported its Q3 2022 results, highlighting a strong financial position with $342.6 million in cash and marketable securities. The ANTLER Phase 1 trial for its lead therapy, CB-010, shows promising early safety and efficacy data for r/r B-NHL patients, with plans to share additional results by year-end. The company submitted an IND application for CB-011 targeting r/r MM and expects further milestones, including CB-020 target selection, in the upcoming months.
Caribou Biosciences (Nasdaq: CRBU) announced its participation in several upcoming investor conferences. Key events include:
- Barclays Gene Editing & Gene Therapy Summit on November 14, 2022
- Jefferies London Healthcare Conference on November 17, 2022
- 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022
- BofA Securities Biotech SMID Cap Conference on December 7, 2022
Webcasts of these presentations will be available for 30 days post-event on Caribou's website.
FAQ
What is the current stock price of Caribou Biosciences (CRBU)?
What is the market cap of Caribou Biosciences (CRBU)?
What does Caribou Biosciences specialize in?
What is CB-010?
What recent FDA feedback did Caribou receive?
How is Caribou's financial health?
What is chRDNA technology?
What are the applications of Caribou's technology?
What designations has CB-010 received from the FDA?
What is the ANTLER trial?
What is Caribou's collaboration with Pfizer?
What upcoming trials are planned for CB-010?
